GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

etesevimab   Click here for help

GtoPdb Ligand ID: 11331

Synonyms: CB-6 | JS-016 | LY-CoV016 | LY3832479
Compound class: Antibody
Comment: Etesevimab (LY3832479) is a monoclonal antibody against the surface spike protein of SARS-CoV-2. It was developed by Eli Lilly, but such is the speed of COVID-19 therapeutic development, there are no peer-reviewed articles that report its design, preclinical or early clinical data.
No information available.
Summary of Clinical Use Click here for help
Was advanced to clinical evaluation for COVID-19, alone and in combination with bamlanivimab (LY3819253, LY-CoV555). The US FDA issued emergency use authorisation (EUA) in 2020, in combination with bamlanivimab. The EUA allowed its use in patients (adult and pediatric) with mild-to-moderate COVID-19 who had received a positive virus test result. The EUA was revoked in the US in early 2021.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04441931 A Study of LY3832479 (LY-CoV016) in Healthy Participants Phase 1 Interventional Eli Lilly and Company
NCT04611789 A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 Phase 1 Interventional Eli Lilly and Company
NCT04427501 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness Phase 2 Interventional Eli Lilly and Company